Pegcetacoplan (Empaveli/Syfovre), developed by Apellis Pharmaceuticals, is a C3 inhibitor initially studied for AMD before it received approval for PNH and, more recently, for geographic atrophy secondary to AMD [63]. This evidence concerns the gene C3 and age-related macular degeneration.